NCT07369505 2026-01-27
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
Phase 1 Recruiting
Clinical Trials
11 trialsNCT07348211 2026-01-23
SIM0610-101
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04778839 2025-08-06
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
First Affiliated Hospital of Zhejiang University
Phase 1 Recruiting
NCT06205849 2025-07-25
Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer
University of California, San Diego
Phase 1 Recruiting
NCT06948539 2025-04-29
To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Not yet recruiting
NCT06913218 2025-04-06
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
Akeso
Phase 1 Not yet recruiting
NCT04676633 2024-03-19
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Sirnaomics
Phase 1 Completed
NCT05193604 2023-12-08
A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Terminated
NCT05765357 2023-03-13
Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With HerceptinĀ® in Healthy Male Volunteers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT05009966 2021-10-25
Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT04625894 2020-11-12
The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in Oligometastatic Gastrointestinal Cancer
Fudan University
Phase 1 Unknown